209 related articles for article (PubMed ID: 27917627)
1. Enhanced Immune Responses against HIV-1 with Adenovector (Gag and Tat) Prime/Protein Boost Regimen and GM-CSF Injection.
Hosseini Rouzbahani N; Bayanolhagh S; Gholami M; Esmaeilzadeh A; Bayat Jozani Z; Mohraz M; Pourfathollah AA
Iran J Allergy Asthma Immunol; 2016 Oct; 15(5):403-412. PubMed ID: 27917627
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
Jaoko W; Karita E; Kayitenkore K; Omosa-Manyonyi G; Allen S; Than S; Adams EM; Graham BS; Koup RA; Bailer RT; Smith C; Dally L; Farah B; Anzala O; Muvunyi CM; Bizimana J; Tarragona-Fiol T; Bergin PJ; Hayes P; Ho M; Loughran K; Komaroff W; Stevens G; Thomson H; Boaz MJ; Cox JH; Schmidt C; Gilmour J; Nabel GJ; Fast P; Bwayo J
PLoS One; 2010 Sep; 5(9):e12873. PubMed ID: 20877623
[TBL] [Abstract][Full Text] [Related]
3. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.
Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y
Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199
[TBL] [Abstract][Full Text] [Related]
4. Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).
Crank MC; Wilson EM; Novik L; Enama ME; Hendel CS; Gu W; Nason MC; Bailer RT; Nabel GJ; McDermott AB; Mascola JR; Koup RA; Ledgerwood JE; Graham BS;
PLoS One; 2016; 11(11):e0166393. PubMed ID: 27846256
[TBL] [Abstract][Full Text] [Related]
5. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).
Churchyard GJ; Morgan C; Adams E; Hural J; Graham BS; Moodie Z; Grove D; Gray G; Bekker LG; McElrath MJ; Tomaras GD; Goepfert P; Kalams S; Baden LR; Lally M; Dolin R; Blattner W; Kalichman A; Figueroa JP; Pape J; Schechter M; Defawe O; De Rosa SC; Montefiori DC; Nabel GJ; Corey L; Keefer MC;
PLoS One; 2011; 6(8):e21225. PubMed ID: 21857901
[TBL] [Abstract][Full Text] [Related]
6. Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines.
Xu R; Megati S; Roopchand V; Luckay A; Masood A; Garcia-Hand D; Rosati M; Weiner DB; Felber BK; Pavlakis GN; Sidhu MK; Eldridge JH; Egan MA
Vaccine; 2008 Sep; 26(37):4819-29. PubMed ID: 18657584
[TBL] [Abstract][Full Text] [Related]
7. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
[TBL] [Abstract][Full Text] [Related]
8. ELISPOT analysis of a new CTL based DNA vaccine for HIV-1 using GM-CSF in DNA prime/peptide boost strategy: GM-CSF induced long-lived memory responses.
Mahdavi M; Ebtekar M; Khorram Khorshid HR; Azadmanesh K; Hartoonian C; Hassan ZM
Immunol Lett; 2011 Oct; 140(1-2):14-20. PubMed ID: 21679728
[TBL] [Abstract][Full Text] [Related]
9. Characterization of immune responses induced by combined clade-A HIV-1 recombinant adenovectors in mice.
Bayanolhagh S; Alinezhad M; Kamali K; Foroughi M; Khorram Khorshid HR; Mohraz M; Mahboudi F; Pourfathollah AA
Iran J Immunol; 2010 Sep; 7(3):162-76. PubMed ID: 20876987
[TBL] [Abstract][Full Text] [Related]
10. Novel vaccination protocol with two live mucosal vectors elicits strong cell-mediated immunity in the vagina and protects against vaginal virus challenge.
Li Z; Zhang M; Zhou C; Zhao X; Iijima N; Frankel FR
J Immunol; 2008 Feb; 180(4):2504-13. PubMed ID: 18250460
[TBL] [Abstract][Full Text] [Related]
11. HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.
Bart PA; Huang Y; Karuna ST; Chappuis S; Gaillard J; Kochar N; Shen X; Allen MA; Ding S; Hural J; Liao HX; Haynes BF; Graham BS; Gilbert PB; McElrath MJ; Montefiori DC; Tomaras GD; Pantaleo G; Frahm N
J Clin Invest; 2014 Nov; 124(11):4843-56. PubMed ID: 25271627
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells.
Dai B; Yang L; Yang H; Hu B; Baltimore D; Wang P
Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20382-7. PubMed ID: 19918062
[TBL] [Abstract][Full Text] [Related]
13. Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA administration elicits potent and protective HIV-specific immune responses.
Tomusange K; Wijesundara D; Gummow J; Wesselingh S; Suhrbier A; Gowans EJ; Grubor-Bauk B
Sci Rep; 2016 Nov; 6():36658. PubMed ID: 27853256
[TBL] [Abstract][Full Text] [Related]
14. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
[TBL] [Abstract][Full Text] [Related]
15. Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy.
Lhomme E; Richert L; Moodie Z; Pasin C; Kalams SA; Morgan C; Self S; De Rosa SC; Thiébaut R
PLoS One; 2016; 11(4):e0152952. PubMed ID: 27124598
[TBL] [Abstract][Full Text] [Related]
16. Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag.
Zhao J; Voltan R; Peng B; Davis-Warren A; Kalyanaraman VS; Alvord WG; Aldrich K; Bernasconi D; Buttò S; Cafaro A; Ensoli B; Robert-Guroff M
Virology; 2005 Nov; 342(1):1-12. PubMed ID: 16109434
[TBL] [Abstract][Full Text] [Related]
17. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses.
Tritel M; Stoddard AM; Flynn BJ; Darrah PA; Wu CY; Wille U; Shah JA; Huang Y; Xu L; Betts MR; Nabel GJ; Seder RA
J Immunol; 2003 Sep; 171(5):2538-47. PubMed ID: 12928404
[TBL] [Abstract][Full Text] [Related]
18. Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.
Chege GK; Burgers WA; Stutz H; Meyers AE; Chapman R; Kiravu A; Bunjun R; Shephard EG; Jacobs WR; Rybicki EP; Williamson AL
J Virol; 2013 May; 87(9):5151-60. PubMed ID: 23449790
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of the immnunogenicity of rAAV2/1 and rAd5 rad5 expressing HIV-1 gag].
Yu SQ; Feng X; Liu HM; Yang HR; Li HX; Zeng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Dec; 23(6):421-3. PubMed ID: 20718344
[TBL] [Abstract][Full Text] [Related]
20. HSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime.
Duke CM; Maguire CA; Keefer MC; Federoff HJ; Bowers WJ; Dewhurst S
Vaccine; 2007 Oct; 25(42):7410-21. PubMed ID: 17868958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
